default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Immunotherapies claims rose on insurance coverage in 2017

Nam Doo-hyun  Published 2018.02.07  11:07  Updated 2018.02.07 15:16

공유
default_news_ad2

More health insurance coverage for expensive immunotherapies caused claims for immunotherapies to rise despite a decline in prescription days last year, government data showed.

According to data from the Health Insurance Review & Assessment Service, claims for therapies to treat malignant tumors exceeded 1.1 trillion won ($1.01 billion) last year, after surpassing 1 trillion won in 2016.

The increase of claims came as the regulator granted health insurance coverage to two leading immunotherapies in August -- Keytruda (ingredient: pembrolizumab) of MSD Korea and Opdivo (ingredient: nivolumab) of Ono Pharmaceutical Korea and BMS Korea.

Pfizer Korea’s breast cancer drug Ibrance (ingredient: palbociclib) and Roche Korea’s bladder cancer treatment Tecentriq (ingredient: atezolizumab) also gained health insurance benefits in November and this past January, respectively.

The prescription days of immunotherapies for malignant tumors fell to 108 million days last year from 122 million days in 2016, and from 147 million days in 2015.

However, health insurance coverage for expensive immunotherapies pushed up the claims to 1.16 trillion won last year compared with 1.09 trillion won in 2016, and 932.1 billion won in 2015.

hwz@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch